Hospitalization costs of adult community-acquired pneumonia in England.

James Campling, Hannah F Wright, Gillian C Hall, Tendai Mugwagwa, Andrew Vyse, Diana Mendes, Mary P E Slack, Gillian F Ellsbury
Author Information
  1. James Campling: Vaccines Medical Affairs, Pfizer Ltd. UK, Tadworth, Surrey, UK. ORCID
  2. Hannah F Wright: Vaccines Medical Affairs, Pfizer Ltd. UK, Tadworth, Surrey, UK. ORCID
  3. Gillian C Hall: Gillian Hall Epidemiology Ltd., London, UK. ORCID
  4. Tendai Mugwagwa: Health & Value, Pfizer Ltd. UK, Tadworth, Surrey, UK. ORCID
  5. Andrew Vyse: Vaccines Medical Affairs, Pfizer Ltd. UK, Tadworth, Surrey, UK. ORCID
  6. Diana Mendes: Health & Value, Pfizer Ltd. UK, Tadworth, Surrey, UK. ORCID
  7. Mary P E Slack: School of Medicine & Dentistry, Griffith University, Southport, Queensland, Australia. ORCID
  8. Gillian F Ellsbury: Vaccines Medical Affairs, Pfizer Ltd. UK, Tadworth, Surrey, UK. ORCID

Abstract

OBJECTIVE: Accurate and up-to-date figures of the cost of community-acquired pneumonia (CAP) hospitalization are needed to understand the associated economic burden for public health decision-makers. Recent estimates are lacking, and previously published estimates differ markedly. Our objective was to estimate the current mean cost to the UK National Health Service (NHS) for adult hospitalized CAP.
METHODS: All CAP hospitalizations in 2019 for those aged ≥18 years were identified from English Hospital Episode Statistics (HES). Each hospitalization was mapped to the tariff cost paid to the care provider within the NHS, including critical care costs and accounting for length of stay and complexity of the case. Mean hospitalization costs were estimated in total and in individuals with defined underlying comorbidities.
RESULTS: A mean cost of £3,904 was estimated for 187,251 CAP admissions providing a total cost of approximately £731 million per annum. The mean cost was £3,402, excluding critical care costs, and £11,654 for critical care episodes in the 4.4% of admissions receiving this care. Groups at high risk of CAP had higher mean costs, ranging from £4,458 for people with diabetes to £5,215 for those with heart disease aged <65 years and £4,356 for those with heart disease to £4,751 for those with liver disease aged >65 years who comprised 74.3% of admissions overall.
CONCLUSION: This estimate of the cost of hospitalization for CAP from the total population and in those with certain underlying comorbidities will allow a valid understanding of the cost-benefit of vaccination and evidence-based prioritization of pneumococcal vaccination to those at highest risk.

Keywords

MeSH Term

Adolescent
Adult
Community-Acquired Infections
England
Health Care Costs
Heart Diseases
Hospitalization
Humans
Pneumonia
State Medicine

Word Cloud

Created with Highcharts 10.0.0costCAPcostscarepneumoniahospitalizationmeancommunity-acquiredNHSagedcriticaltotaladmissionsrisk£4diseaseestimatesestimateadultHospitalestimatedunderlyingcomorbidities£3heartvaccinationpneumococcalOBJECTIVE:Accurateup-to-datefiguresneededunderstandassociatedeconomicburdenpublichealthdecision-makersRecentlackingpreviouslypublisheddiffermarkedlyobjectivecurrentUKNationalHealthServicehospitalizedMETHODS:hospitalizations2019≥18yearsidentifiedEnglishEpisodeStatisticsHESmappedtariffpaidproviderwithinincludingaccountinglengthstaycomplexitycaseMeanindividualsdefinedRESULTS:904187251providingapproximately£731millionperannum402excluding£11654episodes44%receivingGroupshighhigherranging458peoplediabetes£5215<65 years356751liver>65 yearscomprised743%overallCONCLUSION:populationcertainwillallowvalidunderstandingcost-benefitevidence-basedprioritizationhighestHospitalizationEnglandI10I11illnessgroups

Similar Articles

Cited By (8)